v3.26.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Research and development expenses (Note 17) $ (179)
General and administrative expenses, exclusive of depreciation and amortization (Note 18) (5,109) (3,283)
Change in fair value of contingent consideration 1,136
Depreciation and amortization (Note 4) (78)
Operating loss (4,230) (3,283)
Financing expense, net (Note 19) (1,545) (252)
Other income (Note 15(7)) 1,811 428
Changes in fair value of investments measured under the fair value option (Notes 6, 7) 351 (1,212)
Net loss before tax (3,613) (4,319)
Income taxes 18
Net loss from continuing operation (3,595) (4,319)
Net loss from discontinued operations (Note 11) (561) (1,028)
Net loss (4,156) (5,347)
Less: Net loss attributable to non-controlling interests 152 154
Net loss attributable to the Company’s stockholders’ equity $ (4,004) $ (5,193)
Loss per share from continuing operations (basic) (Note 21) [1] $ (3.04) $ (22.25)
Loss per share from discontinued operations (basic) [1] (0.50) (5.49)
Total loss per share (basic) $ (3.54) $ (27.74)
Weighted average number of shares of Common Stock outstanding - basic (Note 21) [1],[2] 1,132,707 187,215
Loss per share from continuing operations (diluted) [1] $ (8.11) $ (22.25)
Loss per share from discontinued operations (diluted) [1] (0.50) (5.49)
Total loss per share (diluted) $ (8.61) $ (27.74)
Weighted average number of shares of Common Stock outstanding – diluted [1] 1,288,249 187,215
Comprehensive income (loss):    
Other comprehensive loss - Foreign currency translation adjustments $ (17)
Comprehensive income (loss) (4,173) (5,347)
Other comprehensive income (loss) attributable to non-controlling interests 157 154
Comprehensive loss attributable to the Company’s stockholders $ (4,016) $ (5,193)
[1] Adjusted to reflect one (1) for thirty-five (35) reverse stock split in September 2025 (see note 1B).
[2] The increase in the weighted average number of shares of common stock outstanding for the year ended December 31, 2025 compared to 2024 reflects shares issued in connection with the MitoCareX acquisition, issuances of common stock under the Company’s PIPE Agreement and SEPA II (including shares issued upon the exercise of warrants issued as part of the PIPE Agreement), and issuances of common stock to service providers and officers.